SCHEDULE: Montanova Capital, LLC Amends Replimune Group Stake

Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amendment to their Schedule 13G, reporting changes in beneficial ownership of Replimune Group, Inc. common stock.

Summary

• This filing is an amendment (Amendment No. 1) to a Schedule 13G, indicating a change in beneficial ownership of Replimune Group, Inc. common stock.
• The reporting persons are Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen.
• Montanova Capital, LLC and Aaron Cowen collectively beneficially own 6,609,000 shares, representing 7.9% of the class.
• Averill Master Fund, Ltd. beneficially owns 5,610,970 shares, representing 6.7% of the class.
• Montanova Capital, LLC is identified as the control person for Aaron Cowen.
• All reported securities are directly owned by advisory clients of Montanova Capital, LLC, with Averill Master Fund, Ltd. being the only advisory client owning more than 5%.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without new financial or strategic information.

Positives

• The filing clarifies the beneficial ownership structure for a significant stake in Replimune Group, Inc.
• It confirms that Montanova Capital, LLC manages these holdings on behalf of its advisory clients.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Replimune Group, Inc.
• It represents an amendment to a previous filing, suggesting a change in holdings rather than a new investment thesis.

Risks

• Changes in beneficial ownership, even if managed by the same entity, can sometimes signal shifts in investment strategy or market sentiment.
• The filing does not offer insights into the reasons behind any potential changes in beneficial ownership percentages.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their holdings. This amendment indicates a potential adjustment in the way these entities hold or report their stake in Replimune Group, Inc., a biotechnology company.

Stakeholder Impact

• Shareholders: May be interested in the aggregate percentage ownership and any potential implications of changes in beneficial ownership, though no specific strategic shift is detailed.
• Management of Replimune Group, Inc.: Will note the updated ownership filings from significant institutional investors.

Next Steps

• Continue to monitor future Schedule 13G filings for any further changes in beneficial ownership by these reporting persons.

Key Dates

Keywords

Replimune Group, Schedule 13G, Beneficial Ownership, Montanova Capital, Averill Master Fund, Aaron Cowen, Investment Management, SEC Filing